Theravance Biopharma Announces Virtual KOL Event Ahead of Key Phase 3 Results for Ampreloxetine in MSA-related nOH

Theravance Biopharma is gearing up for a major clinical milestone. The company will host a virtual KOL investor event on December 8, 2025, led by Dr. Horacio Kaufmann from NYU Langone Health. The session aims to spotlight the clinical need, market opportunity, and upcoming data for ampreloxetine, a late-stage therapy in development for symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA).

Why This Event Matters?

nOH affects nearly 80% of patients with MSA. It causes sharp drops in blood pressure upon standing and severely impacts daily life. Current treatments are limited, and many patients remain symptomatic.

Ampreloxetine offers a potential precision-medicine approach with meaningful clinical benefits observed in earlier trials.

What the Event Will Cover

1. The Unmet Need in MSA-related nOH

• MSA is a rare, progressive neurodegenerative disease.
• nOH is one of its most debilitating symptoms.
• Existing therapies provide incomplete relief for many patients.

2. Clinical Rationale for Ampreloxetine

Dr. Kaufmann will discuss:

• How the drug increases norepinephrine levels.
• Its impact on blood pressure stability.
• Durable symptom improvement seen in Study 0170.
• No worsening of supine hypertension in tested patients.

Ampreloxetine has received Orphan Drug Designation in the U.S. for nOH in MSA.

3. Deep Dive Into the Phase 3 CYPRESS Study

The event will outline the strategic design of Study 0197, which:

• Is a registrational, Phase 3, randomized withdrawal trial.
• Evaluates ampreloxetine over a 20-week treatment duration.
• Uses OHSA composite score as the primary endpoint.
• Includes an open-label phase, double-blind withdrawal, and long-term extension.

Topline data are expected in Q1 2026, making this event highly anticipated.

4. Commercial Strategy and Market Opportunity

Company leadership will explain:

• Why nOH in MSA is a high-value niche with significant unmet need.
• How ampreloxetine could become the first precision therapy for this population.
• The company’s roadmap post-Phase 3 readout, including regulatory submission plans.

A live Q&A session will follow.

About Dr. Horacio Kaufmann

Dr. Kaufmann is a global authority in autonomic disorders. He leads the Dysautonomia Center at NYU Langone and has decades of clinical and research experience across:

• Familial dysautonomia
• Multiple system atrophy
• Pure autonomic failure
• Amyloidosis
• Autonomic neuropathies

His work has contributed to new diagnostic tools, therapeutic innovations, and improved patient care models.

About Multiple System Atrophy & nOH

What is MSA?

A progressive neurological disorder affecting movement, balance, and autonomic functions.

What is nOH?

A sudden drop in blood pressure within 3 minutes of standing.
Symptoms include:

• Dizziness
• Fatigue
• Blurry vision
• Syncope
• Cognitive difficulty
• Weakness

Around 70–90% of MSA patients experience nOH.

About Ampreloxetine

Ampreloxetine is:

• A once-daily, selective norepinephrine reuptake inhibitor.
• Designed to stabilize blood pressure and improve nOH symptoms.
• Being evaluated as a long-term treatment option with durable benefits.

Positive signals from earlier studies support continued late-stage development.

About Theravance Biopharma

Theravance Biopharma focuses on creating medicines that make a difference.
Key assets include:

• YUPELRI®, approved for COPD maintenance therapy.
• Ampreloxetine, now in late-stage testing for nOH in MSA.

The company combines scientific expertise with a commitment to high-impact therapies for serious conditions.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!